Founded in 2021, Bottneuro is developing a non-invasive neuromodulation therapy that utilizes patient-specific MRI data to deliver precise electrical stimulation to affected brain regions. Following the successful closing of its first clinical study, the startup has launched a Priority Access Program and started treating patients with Alzheimer’s Disease in Switzerland.
